Navigation Links
'Difficult-to-treat asthma' may be due to difficult-to-treat patients
Date:10/22/2009

adherence only became apparent using a combination of surrogate and objective measures," said Dr. Heaney. "Of these patients who were referred for assessment and treatment of difficult asthma, many are actually not taking their treatment as prescribed, which would suggest an important first course of action in assessing difficult asthma may actually be verifying the patient's adherence to his or her treatment protocol. Determining whether the patient is taking medications as prescribed is of utmost importance before moving to more aggressive and expensive treatments. It is also crucially important in understanding true refractory disease and assessing responses to novel therapies, either in clinical trials or clinical practice."

Some patient characteristics were more strongly associated with nonadherence than others: women were less likely to be adherent than men, a finding that had been previously identified, but that Dr. Heaney cites as needing more investigation.

Another red flag may be a lower score on quality of life measures. Dr. Heaney and colleagues found that patients who filled fewer than half of their prescribed ICT scored significantly lower on the EuroQol and the Asthma Quality of Life Questionnaire. Furthermore, the number of prior hospital admissions within the past 12 months was significantly associated with non-adherence.

"In general, one might expect in more severe disease that a very poor asthma quality of life score suggesting high morbidity, would perhaps, result in better adherence, " said Dr. Heaney. "The same could be said for hospital admission, but the reasons for non-adherence are complex. However for clinicians, multiple hospital admissions should definitely flag probable non-adherence in difficult-to-treat cases."

"Non-adherence is a common problem, which is often hard to detect. In general, asking the patient or relying on clinical impression is useless, and objective or good surrogate measures shou
'/>"/>

Contact: Keely Savoie
ksavoie@thoracic.org
212-305-8620
American Thoracic Society
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. For Erectile Dysfunction, Physicians Indicate That Opportunity Exists for Emerging Therapies with Improved Efficacy in Difficult-to-Treat Patient Subpopulations
2. Austin, Texas, Physicians Second in Nation to Perform New Procedure for Difficult-to-Treat Atrial Fibrillation Cases
3. Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma
4. New chemotherapy regimen prolongs survival in difficult-to-treat childhood brainstem gliomas
5. Pediatricians put proven treatment strategies to work against childhood asthma
6. Parenting Expert and Family Advocate Jo Frost and Allergy & Asthma Network Mothers of Asthmatics (AANMA) Launch Time 2 Talk Asthma
7. Rising Heat, Humidity Raise Risk of Asthma Flares
8. $450,000 Awarded for Innovative Asthma Research Into Death by Drowning in Mucus
9. Study Demonstrates That QVAR(R) is More Cost-Effective Than Other Inhaled Corticosteroid (ICS) Asthma Therapy Options
10. Chlorine in Pools Raises Kids Asthma, Allergy Risk
11. Day Care May Not Shield Kids From Asthma, Allergies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... , ... For decades, researchers in the genetics field have theorized that the ... changing after development in the womb. Now, researchers from the Icahn School of Medicine ... life – a process which helps to switch genes on and off. This histone ...
(Date:7/1/2015)... York, NY (PRWEB) , ... July 01, 2015 ... ... largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the ... services – today announced that they will welcome four new members to their ...
(Date:7/1/2015)... ORANGE, Calif. (PRWEB) , ... July 01, 2015 ... ... advanced orthodontic technology and services, today announced that its fifth annual Smile for ... has raised $80,000 for the non-profit organization. In addition to supporting S4L in ...
(Date:7/1/2015)... Japan (PRWEB) , ... July 01, 2015 , ... ... 2015 of a new extraction plant for Linablue®, Spirulina-derived natural blue food coloring. ... Nutritionals, LLC, the DIC Group’s U.S. Spirulina* production base, began in May 2014. ...
(Date:7/1/2015)... ... ... The Collaborative for Children and Families (CCF) announced that it received a ... to improve quality of care and save costs for the child welfare sector by ... in New York’s Medicaid system. Experts agree that children need thorough solutions to live ...
Breaking Medicine News(10 mins):Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 2Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 3Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 4Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 2Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 3Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 4Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 5Health News:The Forum Fundraiser Raises $80,000 for the Smile for a Lifetime Foundation 2Health News:The Forum Fundraiser Raises $80,000 for the Smile for a Lifetime Foundation 3Health News:DIC Strengthens Its Position as the Global Leader for Natural Blue Food Coloring 2Health News:DIC Strengthens Its Position as the Global Leader for Natural Blue Food Coloring 3Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 2Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 3
... after markets close at 2:00 p.m. PT (5:00 p.m. ET) ... MASI ), the inventor of Pulse CO-Oximetry and Measure-Through Motion ... quarter and fiscal year 2008 financial results for the period ... March 3, 2009.A conference call to review the results will ...
... Its Roster, Fielding Five Teams to Spread Personal Messages ... 1 and Type 2 DiabetesBRIDGEWATER, N.J., Feb. 5 ... glargine [rDNA origin] injection) and rapid-acting insulin Apidra(R) (insulin ... sponsors of Team Type 1, a team of amateur ...
... Feb. 5 Palomar Medical Technologies, Inc. (Nasdaq: ... light-based systems for cosmetic treatments, today announced financial results ... 2008. Revenues for the quarter ended December 31, ... product revenues, $2.2 million were royalty revenues, $0.5 million ...
... TORONTO, Feb. 5 /PRNewswire-FirstCall/ - Transition Therapeutics Inc. ... TTHI ) today announced the completion of patient ... gastrin analogue, TT-223, in patients with type 2 ... dose-ranging study to evaluate the safety, tolerability and ...
... Health Records (EHRs) have been promoted by industry and ... controlling costs. However, actual adoption of EHRs has ... to implementation costs, security, privacy, and systems integration. ... adoption barriers pale in comparison to basic usability and ...
... and identity theft response leader Kroll Fraud Solutions will host webinars ... a team of Kroll data security experts. , ... ... theft response leader Kroll Fraud Solutions will host a ...
Cached Medicine News:Health News:Masimo to Report Fourth Quarter and Fiscal Year 2008 Financial Results on March 3, 2009 2Health News:Masimo to Report Fourth Quarter and Fiscal Year 2008 Financial Results on March 3, 2009 3Health News:Inspirational Teams of Athletes with Diabetes Build Momentum in 2009 with Sponsorship from Long-Acting Insulin Lantus(R) and Rapid-Acting Insulin Apidra(R) 2Health News:Inspirational Teams of Athletes with Diabetes Build Momentum in 2009 with Sponsorship from Long-Acting Insulin Lantus(R) and Rapid-Acting Insulin Apidra(R) 3Health News:Inspirational Teams of Athletes with Diabetes Build Momentum in 2009 with Sponsorship from Long-Acting Insulin Lantus(R) and Rapid-Acting Insulin Apidra(R) 4Health News:Inspirational Teams of Athletes with Diabetes Build Momentum in 2009 with Sponsorship from Long-Acting Insulin Lantus(R) and Rapid-Acting Insulin Apidra(R) 5Health News:Inspirational Teams of Athletes with Diabetes Build Momentum in 2009 with Sponsorship from Long-Acting Insulin Lantus(R) and Rapid-Acting Insulin Apidra(R) 6Health News:Inspirational Teams of Athletes with Diabetes Build Momentum in 2009 with Sponsorship from Long-Acting Insulin Lantus(R) and Rapid-Acting Insulin Apidra(R) 7Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 2Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 3Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 4Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 5Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 6Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 7Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 8Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 9Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 10Health News:Transition Therapeutics Announces Completion of Patient Enrolment of Phase 2 Study of TT-223 in Type 2 Diabetes Patients 2Health News:How to Select an Electronic Health Record System That Healthcare Professionals Can Use 2Health News:Kroll Fraud Solutions To Host Free Webinar Series on Preparing for and Responding to a Healthcare Data Breach 2
(Date:7/1/2015)... 1, 2015 ExeGi Pharma, a company focused ... announced today that it has been granted a product ... Products Directorate (NNHPD) to sell Visbiome™ in ... by Professor Claudio De Simone , MD, PhD ... Professor De Simone recently signed an exclusive agreement with ...
(Date:7/1/2015)... 2015 According to a new ... Method (Biochemical (Calcium Phosphate, Lipofection, Dendrimers), Physical (Electroporation, Nucleofection), ... Global Forecast to 2020", published by MarketsandMarkets, the Transfection ... $957.9 Million by 2020 with a CAGR of 7.2% ... market T ables and 33 F ...
(Date:7/1/2015)... Mass. , July 1, 2015 Boston Scientific ... discussing financial results and business highlights for the second quarter ... 8 a.m. ET. The call will be hosted ... and Dan Brennan , executive vice president and chief ... call will be available via the Boston Scientific website. Webcast ...
Breaking Medicine Technology:ExeGi Pharma Secures Canadian Approval For Well Studied Probiotic 2ExeGi Pharma Secures Canadian Approval For Well Studied Probiotic 3Transfection Reagents and Equipment Market Worth $957.9 Million by 2020 2Transfection Reagents and Equipment Market Worth $957.9 Million by 2020 3Transfection Reagents and Equipment Market Worth $957.9 Million by 2020 4Boston Scientific To Webcast Second Quarter 2015 Earnings Call On July 23 2
... spinal procedures. The SpineAssist platform for enhancing ... solution that enables surgery to be performed ... currently answers a growing need for accurate ... pedicle screw insertion for spine fusion procedures. ...
ACRYSOF®, Posterior Chamber Intraocular Lenses are indicated for the replacement of the human lens to achieve visual correction of aphakia in patients sixty years and older. These lenses are i...
Single piece PMMA lens, AC depth: 4.7....
Single-Piece PMMA IOLs for the replacement of the human crystalline lens in the visual correction of aphakia....
Medicine Products: